Nektar Therapeutics NKTR Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$158.1M+3.6% | -$164.08M-28.2% | -$128M+1.2% | -$129.53M+7.7% | -$140.3M-11.2% | ||
| $751K-26.8% | $1.03M-12.2% | $1.17M-40.6% | $1.97M-38.8% | $3.21M-26.9% | ||
| $12.11M-4.3% | $12.65M-17.1% | $15.26M-13.2% | $17.58M-9.9% | $19.51M-9.7% | ||
| -$7.97M-1,175% | -$625K-108% | $7.86M-10.9% | $8.82M-12.4% | $10.07M+277% | ||
| -$4.67M+19.2% | -$5.79M— | —— | —— | —— | ||
| $9.53M-42.0% | $16.43M+82.6% | $9M-24.7% | $11.96M+30.5% | $9.17M+119% | ||
| -$6.02M+31.1% | -$8.73M-18.2% | -$7.38M-7.8% | -$6.85M-53.5% | -$4.46M— | ||
| -$5.85M-6.1% | -$5.51M-6.9% | -$5.16M+10.9% | -$5.79M+22.8% | -$7.51M+18.8% | ||
| -$203.76M+2.3% | -$208.51M-9.9% | -$189.74M-2.6% | -$184.91M-4.5% | -$176.87M-0.7% | ||
| $187K+9.4% | $171K-72.1% | $612K-47.4% | $1.16M-11.3% | $1.31M-10.6% | ||
| $712.33M+150% | $285.01M+8.3% | $263.24M+99.3% | $132.06M-27.3% | $181.58M-30.6% | ||
| $316.85M+11.3% | $284.68M+10.4% | $257.81M-3.9% | $268.17M-6.0% | $285.21M-16.2% | ||
| —— | —— | $58.65M-70.6% | $199.63M+19.5% | $167M+17.1% | ||
| —— | $866K+60.7% | $539K+71.7% | $314K+157% | $122K+3.4% | ||
| $710.11M+293% | $180.57M+27.2% | $141.98M+45,116% | $314K+157% | $122K-99.7% | ||
| $7K+16.7% | $6K— | —— | —— | —— | ||
| —— | —— | —— | —— | -$9.75M-209% | ||
| $12.11M-4.3% | $12.65M-17.1% | $15.26M-13.2% | $17.58M-9.9% | $19.51M-9.7% | ||
| -$5.85M-6.1% | -$5.51M-6.9% | -$5.16M+10.9% | -$5.79M+22.8% | -$7.51M+18.8% | ||
| —— | $0-100% | $10.1M-50.0% | $20.2M-33.3% | $30.29M-25.0% | ||
| -$6.02M+31.1% | -$8.73M-18.2% | -$7.38M-7.8% | -$6.85M-53.5% | -$4.46M— | ||
| $15.75M+3.9% | $15.16M+3.2% | $14.69M+2.8% | $14.29M+21.5% | $11.76M-8.9% | ||
| -$4.67M+19.2% | -$5.79M— | —— | —— | —— | ||
| $9.53M-42.0% | $16.43M+82.6% | $9M-24.7% | $11.96M+30.5% | $9.17M+119% | ||
| $29.15M+11.3% | $26.18M-1.4% | $26.57M+0.1% | $26.54M-3.7% | $27.56M-2.0% | ||
| $55.33M+0.7% | $54.93M+11.3% | $49.36M-7.9% | $53.6M-9.5% | $59.22M-7.9% | ||
| —— | —— | —— | —— | —— | ||
| $316.85M+11.3% | $284.68M+10.4% | $257.81M-3.9% | $268.17M-6.0% | $285.21M-16.2% | ||
| —— | -$697K-104% | $15.82M-51.1% | $32.34M-33.8% | $48.87M-25.3% | ||
| —— | —— | —— | —— | —— | ||
| $4.91M+467% | $866K+60.7% | $539K+71.7% | $314K+157% | $122K+3.4% | ||
| —— | $0-100% | $3.05M-50.0% | $6.11M-33.3% | $9.16M-25.0% | ||
| —— | $0-100% | $174.25K-50.0% | $348.5K-33.3% | $522.75K-25.0% | ||
| -$203.94M+2.3% | -$208.68M-9.6% | -$190.35M-2.3% | -$186.07M-4.4% | -$178.19M-0.6% | ||
| -$203.94M+2.3% | -$208.68M-9.6% | -$190.35M-2.3% | -$186.07M-4.4% | -$178.19M-0.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Nektar Therapeutics generate?
- Nektar Therapeutics (NKTR) generated -$203.8M in operating cash flow over the trailing twelve months.
- What is Nektar Therapeutics's free cash flow?
- After $187.0K of capital expenditures, Nektar Therapeutics's free cash flow was -$203.9M over the trailing twelve months, down 14.4% year over year.
- Where does Nektar Therapeutics's cash flow data come from?
- Every line is extracted from Nektar Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
